Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

Racial-Ethnic Disparities in Pediatric AML Vary Across Cytogenetic Subclasses

A recent study published in Blood Advances showed that cytogenic lesions in children with acute myeloid leukemia (AML) differ by race-ethnicity, with higher rates...

Brexucabtagene Autoleucel Approved for Relapsed or Refractory B-Cell Precursor ALL

The U.S. Food and Drug Administration (FDA) has approved CD19-directed chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel for the treatment of adult patients...

Evaluating a Machine Learning Approach for the Detection of AML

Researchers led by Jan-Niklas Eckardt, MD, of the Technical University Dresden in Germany, have developed a machine learning approach that allows for rapid and...
WIB_icon

Routine Screening for Germline Variants in Patients With AML

Nearly 14% of adult patients with acute myeloid leukemia (AML) have pathogenic or likely pathogenic germline variants that make them susceptible to myeloid malignancies,...

Modified EASIX Score Predicts CRS and ICANS Before Severe Symptoms in Patients With B-Cell...

A modified version of the EASIX (Endothelial Activation and Stress Index) score, when calculated prior to and soon after chimeric antigen receptor (CAR) T-cell...

FDA Places Clinical Hold on Trials of AZD5991 Following Cardiac Complications

On October 9, the U.S. Food and Drug Administration (FDA) placed a clinical hold on a trial assessing AstraZeneca’s AZD5991 in combination with venetoclax...

Study Explores Molecular Landscape, Prognostic Impact of FLT3-ITD Insertion Site in Patients With AML

In an analysis of the phase III RATIFY trial published in Leukemia, researchers examined the molecular landscape of FLT3 internal tandem duplication (ITD) mutations...
WIB_icon

Flow Cytometry as a Prognostic Tool for Children With Down Syndrome and AML

The use of flow cytometry alone to determine measurable residual disease (MRD) status did not sufficiently identify children with acute myeloid leukemia (AML) and...

Treatment Delays and Hemostatic Abnormalities Predict Death in Newly Diagnosed APL

Major factors associated with early deaths in hospitalized patients with newly diagnosed acute promyelocytic leukemia (APL) included treatment delays and the incidence of hemostatic...

Oblimersen Shows No Added Benefit in Newly Diagnosed Acute Myeloid Leukemia

The addition of BCL-2 antisense oligonucleotide oblimersen to standard induction chemotherapy did not improve remission rates in older patients with newly diagnosed acute myeloid...